Abstract:To the Editor: We appreciate the comments by Levesque and colleagues and that they have brought attention to the consistencies between our data using the genetic Acvr1R206H/+ mouse model of heterotopic ossification (HO) and their model of HO formation in wild-type mice with spinal cord injury (SCI)-induced neurogenic heterotopic ossification (Genet and colleagues1 and Torossian and colleagues2). We agree that together these studies provide strong support for cytokine production by macrophages as a common inducer of HO. We previously have discussed common immunological contributions among multiple HO disorders,3 and the investigations of neurogenic heterotopic ossification (NHO)1, 2 importantly emphasize the role of macrophages and identify the cytokine Oncostatin M in a SCI and injury model that faithfully replicates symptoms of NHO. Our study investigating the role of inflammation in the initiation and development of HO in the rare genetic disorder fibrodysplasia ossifications progressiva (FOP)4 further emphasizes the integral role of inflammation and immune cells in HO pathology. In both our FOP Acvr1R206H/+ model and the NHO/SCI model, cardiotoxin injury to skeletal muscle was used to induce HO. We identified a robust cellular and molecular inflammatory response to injury in our Acvr1R206H model of HO4 with increased presence of innate immune cells, including macrophages and mast cells, as well as increased expression of proinflammatory cytokines, in mutant mice compared to controls. Upon depleting macrophages using clodronate-liposomes—also the same approach used by Genet and colleagues1—we likewise observed a significant decrease in HO formation.4 The relevancy of macrophages and cytokines in the development of HO across multiple disorders is becoming increasingly apparent. In addition to our study and the aforementioned NHO studies, macrophages have been implicated in the development of cardiac HO5 and in a BMP4 overexpression HO model that showed robustly reduced HO formation in response to clodronate-liposome-mediated depletion of macrophages.6 Furthermore, IL-6, a cytokine that we determined to be highly upregulated in Acvr1R206H/+ mutant tissue postinjury and in mast cells,4 has been previously reported as a predictive biomarker for HO development in blast injury patients,7, 8 as noted in our Discussion.4 We also want to highlight the contribution of mast cells to HO development in both FOP and nongenetic HO disorders. Genet and colleagues1 identified Substance P as a secreted factor that was significantly upregulated in human NHO patients, and treatment of their NHO/SCI model with an antagonist of Nk1r (the obligate Substance P receptor) significantly reduced HO volume. Notably, high levels of Substance P have been observed in early lesion biopsies from FOP patients,9 and inhibition of the Substance P neuroinflammatory pathway impaired HO in BMP4 overexpression and BMP2 implant models.9, 10 Our in vivo results showed that genetic ablation of mast cells in Acvr1R206H/+ mutant mice reduced HO volume similarly to macrophage depletion, and that combined depletion of both cell populations resulted in further reduction of HO formation.4 Our group further reported that inhibition of mast cell degranulation by cromolyn reduced HO formation.11 These data support that mast cells are additionally integral to the development of HO. The overlapping inflammatory features among genetic and nongenetic HO disorders has increasingly been confirmed over recent years, and future studies will further clarify commonalities, such as the role of additional cytokines, macrophage polarization, and other immune cell contributions to HO formation. Although it is important to note the unique aspects of FOP pathology, including accelerated cartilage and bone cell differentiation caused by the R206H mutation,12, 13 we fully agree with Levesque and colleagues that the overlapping inflammatory features among genetic and nongenetic HO disorders establishes the immune system as an attractive target for therapeutic intervention for all affected patients. All the authors state that they have no conflicts of interests.

Role of the NF-kB signalling pathway in heterotopic ossification: biological and therapeutic significance

NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification

Involvement of the Wnt/β‐catenin signalling pathway in heterotopic ossification and ossification‐related diseases

Reciprocal Inhibition of YAP/TAZ and NF-κB Regulates Osteoarthritic Cartilage Degradation

mTORC1 coordinates NF-κB signaling pathway to promote chondrogenic differentiation of tendon cells in heterotopic ossification

Role of hedgehog signaling in the pathogenesis and therapy of heterotopic ossification

Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification

The hypoxic microenvironment: a driving force for heterotopic ossification progression

The role of miRNAs as biomarkers in heterotopic ossification

BMP and mTOR signaling in heterotopic ossification: Does their crosstalk provide therapeutic opportunities?

The role of NF-κB-SOX9 signalling pathway in osteoarthritis

NF-κB Modulators in Osteolytic Bone Diseases

Inhibition of overactive TGF-β attenuates progression of heterotopic ossification in mice

NF-κB Signaling Regulates Physiological and Pathological Chondrogenesis

Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway

The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification

Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification

Reply To: Macrophages Driving Heterotopic Ossification: Convergence of Genetically‐Driven and Trauma‐Driven Mechanisms

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Macrophages in heterotopic ossification: from mechanisms to therapy

Critical Roles of NF-κB Signaling Molecules in Bone Metabolism Revealed by Genetic Mutations in Osteopetrosis